Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

ABX464Positive

AI Analysis

Summary

Market analysis report projects strong growth in the inflammatory bowel disease market through 2036, driven by emerging therapies including ABX464 from Abivax targeting IL-23, TL1A, and S1P pathways.

Importance:3/10

Sentiment:

0.50

inflammatory bowel diseasemarket analysisdrug developmentIL-23TL1AS1P pathways

Related Companies

$ABVX.PA

Read the original article

Published by PR Newswire Biotech on July 30, 2026 2:31 PM

Read Original